AOP-Wiki

API

All Key Events

Showing 151 to 175 of 1921 Key Events

ID	Title	Event Component Count	Biological Organization	Created At	Last Updated	AOPs

2273	Dihydrotestosterone (DHT) levels, increased Short Name	1	Tissue	Nov 2, 2024	Nov 2, 2024	None
2272	Testosterone levels, increased Short Name Testosterone levels, increased	1	Tissue	Nov 2, 2024	Nov 2, 2024	None
2271	Increased, plasma low-density lipoprotein (LDL) cholesterol Short Name Increased, plasma LDL cholesterol	1	Tissue	Oct 22, 2024	Feb 10, 2025	2 AOPs 545: Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased cholesterol synthesis 548: Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased PCSK9 protein expression
2270	Increased, cholesterol synthesis enzymes Short Name	1	Cellular	Oct 22, 2024	Feb 10, 2025	545: Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased cholesterol synthesis
2269	Increased, Sterol Regulatory Element Binding Protein 2 (SREBP2) protein expression Short Name Increased, SREBP2 protein expression	1	Cellular	Oct 22, 2024	Feb 10, 2025	2 AOPs 545: Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased cholesterol synthesis 548: Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased PCSK9 protein expression
2268	Decreased, insulin-induced gene 1 (INSIG1) protein activity Short Name Decreased, INSIG1 protein activity	1	Cellular	Oct 22, 2024	Feb 10, 2025	2 AOPs 545: Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased cholesterol synthesis 548: Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased PCSK9 protein expression
2267	Delayed neuropathy, increased Short Name Delayed neuropathy, increased	0	Individual	Oct 1, 2024	Oct 1, 2024	2 AOPs 543: Inhibition of neuropathy target esterase leading to delayed neuropathy via lysolecithin cell membrane integration 544: Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation
2266	Demyelination, increased Short Name Demyelination, increased	2	Cellular	Oct 1, 2024	Oct 1, 2024	3 AOPs 543: Inhibition of neuropathy target esterase leading to delayed neuropathy via lysolecithin cell membrane integration 544: Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation 610: Decreased thyroid hormone levels in the brain regulated via transport, metabolism and TR activation leading to decreased cognition and motor function
2265	Oligodendrocyte death, increased Short Name Oligodendrocyte death, increased	1	Cellular	Oct 1, 2024	Oct 1, 2024	2 AOPs 543: Inhibition of neuropathy target esterase leading to delayed neuropathy via lysolecithin cell membrane integration 544: Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation
2264	Lysolecithin cell membrane integration, increased Short Name	0	Cellular	Oct 1, 2024	Oct 1, 2024	543: Inhibition of neuropathy target esterase leading to delayed neuropathy via lysolecithin cell membrane integration
2263	Lysolecithin, increased Short Name LPS, increased	1	Cellular	Oct 1, 2024	Oct 1, 2024	2 AOPs 543: Inhibition of neuropathy target esterase leading to delayed neuropathy via lysolecithin cell membrane integration 544: Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation
2262	Neuropathy target esterase, inhibited Short Name NTE, inhibited	1	Molecular	Oct 1, 2024	Oct 1, 2024	2 AOPs 543: Inhibition of neuropathy target esterase leading to delayed neuropathy via lysolecithin cell membrane integration 544: Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation
2261	Decreased, blood plasma volume Short Name Decreased, blood plasma volume	1	Tissue	Sep 20, 2024	Dec 3, 2024	539: Decreased Sodium/Potassium ATPase activity leads to Heart failure
2260	Gluten-reactive CD4+ T cells, activation Short Name	1	Cellular	Sep 13, 2024	Jan 4, 2025	524: Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals
2259	Altered, Microbial Bile Acid Metabolism Short Name Microbial Bile Acid Dysmetabolism	0	Molecular	Aug 29, 2024	Aug 29, 2024	None
2258	Inhibition, monocarboxylate transporter 8 (MCT8) Short Name	1	Molecular	Aug 28, 2024	Nov 24, 2025	610: Decreased thyroid hormone levels in the brain regulated via transport, metabolism and TR activation leading to decreased cognition and motor function
2257	Celiac disease Short Name Celiac disease	1	Individual	Aug 13, 2024	Dec 2, 2024	524: Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals
2256	Gluten-reactive B cells and transglutaminase 2-reactive B cells, activation Short Name	1	Cellular	Aug 13, 2024	Jan 4, 2025	524: Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals
2255	Innate immune response, activation Short Name	1	Cellular	Aug 13, 2024	Apr 3, 2025	524: Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals
2254	Gluten-reactive and transglutaminase 2 reactive B cell receptors, generation Short Name	1	Molecular	Aug 13, 2024	Dec 3, 2024	524: Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals
2253	Gluten-reactive T cell receptors, generation Short Name	1	Molecular	Aug 13, 2024	Jan 5, 2025	524: Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals
2252	Human leukocyte antigen DQ2/8-gluten complexes, formation Short Name Formation of HLA-DQ2/8-gluten complexes	1	Molecular	Aug 13, 2024	Jan 5, 2025	524: Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals
2251	Estradiol availability, increased Short Name Increased E2 availability	2	Tissue	Aug 9, 2024	Nov 21, 2024	4 AOPs 504: SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level 561: Aromatase induction leading to estrogen receptor alpha activation via increased estradiol 565: 17β-Hydroxysteroid dehydrogenase 2, inhibition leading to activation, estrogen receptor alpha 566: Decreased, GnRH pulsatility/release leading to estradiol availability, increased via impaired ovulation
2250	17β-Hydroxysteroid dehydrogenase 2, inhibition Short Name HSD17B2 inhibition	0	Molecular	Aug 9, 2024	Aug 12, 2024	565: 17β-Hydroxysteroid dehydrogenase 2, inhibition leading to activation, estrogen receptor alpha
2249	Activation of sensory receptors Short Name Activation of sensory receptors	0	Molecular	Jul 29, 2024	Jul 29, 2024	None